Management of Resistance to Androgen Deprivation Therapy in Prostate Cancer
When prostate cancer progresses to castration-resistant disease (CRPC), continue ADT to maintain castrate testosterone levels (<50 ng/dL) and add sequential therapies based on prior treatment history, biomarker status, and disease characteristics. 1, 2
Initial Assessment at Castration Resistance
When disease progresses on ADT, immediately:
- Confirm castrate testosterone level (<50 ng/dL or <1.7 nmol/L) 2
- Perform metastatic lesion biopsy if feasible
- Test for MSI-H/dMMR status (if not previously done) 1, 2
- Test for HRR gene alterations (BRCA1/2, ATM, PALB2, FANCA, RAD51D, CHEK2, CDK12) - both germline and tumor 1, 2
- Obtain PSMA-PET imaging for treatment planning 1, 2
- Assess tumor mutational burden (TMB) 2
Critical pitfall: Never discontinue ADT when disease becomes castration-resistant. The androgen receptor pathway remains the primary driver even in resistant disease. 2, 3
Treatment Algorithm Based on Prior Therapy
For Patients Previously on ADT Alone (No Prior ARPI or Docetaxel)
First-line options 1:
- Abiraterone + prednisone (PFS HR 0.66, OS HR 0.74) OR
- Enzalutamide (PFS HR 0.40, OS HR 0.63)
Special populations:
- HRR gene alterations (especially BRCA1/2): Combine PARP inhibitor with ARPI for superior survival benefit 1
- MSI-H or dMMR: Pembrolizumab 1, 2
- Bone-only symptomatic disease: Radium-223 1, 2
- Oligometastatic disease: Consider metastasis-directed radiation or surgery after multidisciplinary discussion 1
- Indolent disease (PSADT >10 months, asymptomatic, low-volume): Sipuleucel-T or continued monitoring 1, 2
For Patients Previously on ADT + Docetaxel (No Prior ARPI)
Preferred options 1:
- Abiraterone + prednisone (PFS HR 0.66, OS HR 0.74) OR
- Enzalutamide (PFS HR 0.40, OS HR 0.63)
Alternative: Cabazitaxel (PFS HR 0.74, OS HR 0.70 vs mitoxantrone) 1
For Patients Previously on ADT + ARPI + Docetaxel (Triple Therapy)
This represents the most challenging scenario with inherently resistant disease. Treatment selection depends critically on biomarker status 1:
PSMA-positive disease:
- 177Lu-PSMA-617 (preferred) - PFS HR 0.40, OS HR 0.62 1
HRR gene alterations (BRCA1/2, ATM, etc.):
- Olaparib monotherapy - PFS HR 0.49 (though OS benefit not statistically significant: HR 0.79) 1
- Rucaparib (TRITON-3 data) 1
PSMA-negative, HRR-negative disease:
- Cabazitaxel (especially if prior ARPI was enzalutamide or abiraterone - CARD trial showed PFS HR 0.54, OS HR 0.64 vs switching ARPIs) 1
- Radium-223 for bone-only symptomatic disease 1
- Pembrolizumab if MSI-H/dMMR 1
Heavily pretreated patients:
- Cabazitaxel + carboplatin (PFS HR 0.69 vs cabazitaxel alone) 1
- Carboplatin monotherapy
- Best supportive care with palliative intent 1
Key Sequencing Principles
The CARD trial fundamentally changed treatment sequencing: In patients progressing on an ARPI, cabazitaxel is superior to switching to another ARPI (abiraterone or enzalutamide), with significant PFS and OS benefits. 1 This means cross-resistance between ARPIs is substantial, and chemotherapy should be prioritized over ARPI switching in most cases.
Early biomarker testing is essential: Given significant patient attrition with each line of therapy in real-world practice, identify HRR alterations and PSMA status before starting mCRPC treatment to optimize first-line therapy and avoid missing opportunities for targeted treatments. 1
BRCA1/2 alterations warrant immediate attention: These patients derive the most significant survival benefit from PARP inhibitor combinations, making early genetic testing critical. 1
Mechanisms of Resistance to Consider
While treatment decisions are algorithm-based, understanding resistance mechanisms helps anticipate progression 3, 4, 5:
- AR amplification and mutations (especially ligand-binding domain mutations)
- AR splice variants (AR-V7)
- Increased intratumoral androgen synthesis
- Activation of alternative pathways (PI3K/AKT, glucocorticoid receptor)
- Neuroendocrine differentiation
- DNA repair defects
- Lineage plasticity
These mechanisms inform emerging therapies including AR degraders (PROTACs), non-ligand binding domain inhibitors, CYP11A1 inhibitors, and bipolar androgen therapy, though most remain investigational. 4, 5, 6
Common Pitfalls to Avoid
- Stopping ADT at castration resistance - This accelerates progression 2
- Delaying biomarker testing - HRR and PSMA status should be known before selecting mCRPC therapy 1
- Sequential ARPI use without intervening chemotherapy - CARD trial shows this is inferior to cabazitaxel 1
- Missing MSI-H/dMMR patients - These respond to pembrolizumab regardless of other factors 1, 2
- Failing to refer BRCA-positive patients for genetic counseling - Family cascade testing is indicated 2
Supportive Care Throughout
All patients with mCRPC should receive best supportive care addressing ADT-related adverse effects including cardiovascular risk, bone health, metabolic complications, and quality of life concerns. 2, 7